Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $7.1 million.

  • Centessa Pharmaceuticals' Net Cash Flow fell 9737.72% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$345.1 million, marking a year-over-year decrease of 25281.64%. This contributed to the annual value of $254.0 million for FY2024, which is 19539.31% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Net Cash Flow is $7.1 million, which was down 9737.72% from -$60.8 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Net Cash Flow registered a high of $269.6 million during Q3 2024, and its lowest value of -$276.5 million during Q1 2025.
  • For the 4-year period, Centessa Pharmaceuticals' Net Cash Flow averaged around -$36.2 million, with its median value being -$43.0 million (2023).
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 93445.39% in 2024, then tumbled by 265693.35% in 2025.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Net Cash Flow stood at -$51.9 million in 2022, then grew by 17.25% to -$43.0 million in 2023, then surged by 65.47% to -$14.8 million in 2024, then soared by 147.65% to $7.1 million in 2025.
  • Its Net Cash Flow was $7.1 million in Q3 2025, compared to -$60.8 million in Q2 2025 and -$276.5 million in Q1 2025.